AUA 2015 - Bladder Cancer

REVIEW UroToday

Viewing 1-20 of 22 articles

#AUA15 - After 15 years, former smokers can lower their risk of recurrence of non-muscle invasive bladder cancer - Session Highlights

#AUA15 - Older patients’ UTI symptoms may predict for bladder cancer, especially among women - Session Highlights

#AUA15 - Medical comorbidities, not neoadjuvant chemotherapy, affects decline in renal function following radical cystectomy and eligibility for platinum based adjuvant chemotherapy - Session Highlights

#AUA15 - Neoadjuvant chemotherapy (NAC) has no adverse effect on radical cystectomy (RC) or perioperative complications - Session Highlights

#AUA15 - White blood cell count at discharge following radical cystectomy associates with risk for readmission - Session Highlights

#AUA15 - Role contemporary pre-cystectomy nomograms at predicting locally advanced and metastatic urothelial bladder cancer - Session Highlights

#AUA15 - Societe Internationale D’Urologie (SIU) Lecture: Redefining optimal surgical management of muscle invasive bladder cancer - Session Highlights

#AUA15 - State-of-the-Art Lecture: Bacillus Calmette-Guerin (BCG) refractory carcinoma in situ (CIS) of the bladder - Session Highlights

#AUA15 - State-of-the-Art Lecture: Contemporary update on treatment of non-invasive bladder cancer - Session Highlights

#AUA15 - Mutation in MUC6 predicts overall and recurrence-free survival following radical cystectomy for muscle-invasive bladder cancer - Session Highlights

#AUA15 - Tumor PD-L1 and lymphocytic infiltrate FOXP3 status in non-muscle invasive urothelial carcinoma of the bladder (NMIBC) - Session Highlights

#AUA15 - Use of linear discriminant analysis in a urine-based test for bladder cancer diagnosis - Session Highlights

#AUA15 - Hematuria practice patterns in the primary care setting - Session Highlights

#AUA15 - Epithelial tumor markers (CA 125, CA 19-9, CEA) trends in patients undergoing treatment for invasive bladder cancer - Session Highlights

#AUA15 - Rising Star Report: Optimizing survivorship and decision-making in low risk bladder cancer - Session Highlights

#AUA15 - Treatment delays in the management of muscle-invasive bladder cancer: Analysis of the National Cancer Database - Session Highlights

#AUA15 - Pathologic assessment at the time of TURBT: Can your initial pathologic report be trusted when making treatment decisions - Session Highlights

#AUA15 - Technical solutions to improve the management of non-muscle invasive transitional cell carcinoma - Session Highlights

#AUA15 - Measuring success after radical cystectomy: feasibility of a novel composite endpoint (“poor recovery”) to quantify outcomes after surgery - Session Highlights

#AUA15 - Crossfire: Controversies in Urology: Bladder sparing for invasive bladder cancer is not cancer sparing - Session Highlights

1
2